Combination of anti-PD-1 and anti-CTLA-4 therapies have achieved 50% overall survival (OS) for patients with advanced metastatic disease in clinical trials establishing ICI as standard therapy in advanced or metastatic melanoma (1). This evidence concerns the gene PDCD1 and metastatic melanoma.